GLP-1 Collective

Policy Tracker · Patient Lens · July 27, 2026

Four lawsuits, one question: who set Ozempic's price and why

A hospital, a patient, and a fresh complaint all point back at how Novo Nordisk and Lilly market and price their GLP-1 drugs.

4 developments affecting GLP-1 access were tracked on Sunday, July 26, 2026, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Lawsuit targets Novo Nordisk's GLP-1 marketing practices](/lawsuits/cl-73678318)**.

**[Baker v. Novo Nordisk: What's the lawsuit about?](/lawsuits/cl-73677848)**.

**[Henrickson sues Novo Nordisk over Ozempic pricing](/lawsuits/cl-73677615)**.

**[Hospital sues Eli Lilly over GLP-1 pricing tactics](/lawsuits/cl-73678587)**.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.